Ozempic has become somewhat of a buzzword thanks to its alleged use by high-profile celebrities and social media influencers for weight loss, in addition to those who use it as part of their treatment plan for diabetes.
Learn more about how Ozempic works for weight loss and blood sugar control in people living with diabetes here.
References
Cabou, C., et al. (2011). GLP-1, the gut-brain, and brain-periphery axes. The Review of Diabetic Studies: RDS.
Frías, J. P., et al. (2021). Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): A double-blind, randomised, phase 3b trial. The Lancet. Diabetes & Endocrinology.
Frías, J. P., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine.
Ronveaux, C C., et al. (2015). Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. The Journal of Nutrition.
Sorli, C., et al. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet. Diabetes & Endocrinology.
Why trust our experts?













